Former Executive Director Of BioPharma Company To Lead Discussion On The Transition Of Molecules From Discovery To Development
DURHAM, N.C., May 16, 2017 – Avista Pharma Solutions, Inc. (“Avista Pharma”) has announced that Dr. Michael Hageman, former executive director of discovery pharmaceutics at Bristol-Myers Squibb, will lead an Insight Briefing on behalf of Avista Pharma at the combined InformEx and CPhI North America conference in Philadelphia. The seminar will take place on Tuesday, May 16 from 3:30 to 4:15 p.m. on the InformEx exhibition floor. Avista Pharma will be located at booth 2929.
Dr. Hageman holds a doctorate in pharmaceutical chemistry, and in this seminar, he will lead a discussion on the necessary integrated process of transitioning molecules from discovery to development. In addition, he will emphasize the critical importance of the development of analytical methods and physicochemical properties in this process for the successful progression of today’s drug candidates.
“Dr. Hageman is well known in the pharmaceutical industry for his expertise in the advancement of new molecular entities from discovery to development with strong pre-formulation packages to ensure a greater success rate for the compounds as they progress through their life cycle,” said Timothy Compton, vice president of business development at Avista Pharma. “Dr. Hageman’s expertise will be an asset in speaking on behalf of Avista Pharma’s efforts and discussing the importance of well characterized molecules in early stage development, an area that Avista Pharma is highly skilled in to overcome the development challenges our clients face.”
Dr. Hageman has more than 30 years of experience within the pharmaceutical industry, including at Upjohn, Pharmacia, Pfizer, and for the last 11 years, Bristol-Myers Squibb. He has worked with discovery organizations for the design and selection of developable molecules, including both small molecules and larger protein biologics. In his work, Hageman incorporated the critical steps of physicochemical property prediction and characterization, including preformulation and design of enabled formulations for enhanced bioavailability, to ensure a successful progression of the drug candidates.
Dr. Hageman is an editor for the Journal of Pharmaceutical Sciences and chairs the Pharmaceutics Advisory Committee for PhRMA Foundation. He has also served as chair of the physical pharmacy and biopharmaceutics section for AAPS and been involved in the organization of more than 10 symposia at AAPS-sponsored meetings. He has authored nearly 50 publications, 12 patents/applications, 80 invited presentations and more than 65 meeting presentations. He has co-edited two books, entitled Prodrugs: Challenges and Rewards and Optimizing the Drug-Like Properties of Leads in Drug Discovery.
He obtained his bachelor of science in pharmacy and his doctorate in pharmaceutical chemistry from the University of Kansas. He has been an adjunct professor at Purdue University, the University of Kansas and the University of Utah, serving on six different thesis committees.
